Pharmaceuticals News and Research

RSS

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.

18 Jun 2013

MCL-1 protein is vital for normal heart function, shows study

A study by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences and the Department of Pharmacology at the University of California, San Diego, shows that a protein called MCL-1, which promotes cell survival, is essential for normal heart function.

18 Jun 2013

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.

18 Jun 2013

Vanda presents additional data from tasimelteon Phase III studies at ENDO 2013

Vanda Pharmaceuticals Inc. presented additional data today at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms.

18 Jun 2013

TSRI scientists identify highly promising new anti-tuberculosis compound

An international team led by scientists at The Scripps Research Institute, the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis bacterium in two different ways.

18 Jun 2013

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Genmab A/S and ADC Therapeutics Sarl, announced today an agreement to develop a new antibody-drug conjugate product combining Genmab's HuMax-TAC antibody and ADC Therapeutics' PBD-based warhead and linker technology.

17 Jun 2013

Mount Sinai researchers present several new studies at ENDO 2013

Researchers from the Icahn School of Medicine at Mount Sinai will present several new studies at ENDO 2013, The Endocrine Society's Annual Meeting & Expo from June 15-18 in San Francisco.

17 Jun 2013

Eli Lilly, BIPI support ADA's call for independent review of incretin-based therapies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company support the American Diabetes Association call for an independent review of the safety data of incretin-based therapies.

17 Jun 2013

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.

17 Jun 2013

Study surveys physicians regarding prescribing of brand drugs over generics

In the fight to win new patients, the importance of prescription sampling programs has never been greater.

15 Jun 2013

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young Entrepreneur Of The Year® 2013 Award in the Life Sciences category in New Jersey. Dr. Nader was presented with the award at a special gala event on June 13 at the Hyatt Regency New Brunswick, New Jersey.

15 Jun 2013

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

Emory University today announced an innovative new public-private drug development enterprise that will transition scientific discoveries more rapidly and efficiently from university laboratories into the marketplace. The new venture is expected to provide global solutions to address worldwide drug development and commercialization needs.

15 Jun 2013

Amedra Pharmaceuticals re-launches single-dose epinephrine auto-injector, Adrenaclick

Amedra Pharmaceuticals LLC has announced re-launch of Adrenaclick®, a single-dose epinephrine auto-injector, for the emergency treatment of life threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Adrenaclick® will be available as a two-pack carton in both 0.15 mg and 0.30 mg strengths.

15 Jun 2013

Pfizer receives $2.15 billion settlement from Teva and Sun for patent-infringement damages

Pfizer Inc. announced today a $2.15 billion settlement reached with Teva Pharmaceuticals Industries, Limited and Sun Pharmaceutical Industries, Limited for patent-infringement damages resulting from their "at-risk" launches of generic Protonix® in the United States.

15 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

InterMune, Inc. today announced that the Board of the Italian Drug Agency has approved the pricing and reimbursement conditions for Esbriet (pirfenidone), and that the agreement has been published in the Official Gazette, the official journal of the government of Italy.

15 Jun 2013

Lineage Therapeutics announces US launch of generic epinephrine auto-injector

Lineage Therapeutics Inc. has announced the US launch of its generic epinephrine injection, USP auto-injector, the authorized generic of Adrenaclick by Amedra Pharmaceuticals LLC, for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis.

15 Jun 2013

NICE Appraisal Committee reconfirms clinical effectiveness of ILUVIEN

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence has issued a positive Appraisal Consultation Document on ILUVIEN for the treatment of pseudophakic patients with chronic diabetic macular edema considered insufficiently responsive to available therapies.

14 Jun 2013

Research: Older adults who volunteer for work decrease their risk of hypertension

New research from Carnegie Mellon University shows that older adults who volunteer for at least 200 hours per year decrease their risk of hypertension, or high blood pressure, by 40 percent.

14 Jun 2013

IPC to distribute AP's Promescent in US for treatment of premature ejaculation

The Independent Pharmacy Cooperative and Absorption Pharmaceuticals have signed a distribution agreement whereby IPC will make AP's topical treatment for premature ejaculation, Promescent, available to its 4,500+ member pharmacies throughout the United States.

14 Jun 2013

Pharmaceuticals News and Research

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

MCL-1 protein is vital for normal heart function, shows study

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Vanda presents additional data from tasimelteon Phase III studies at ENDO 2013

TSRI scientists identify highly promising new anti-tuberculosis compound

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Mount Sinai researchers present several new studies at ENDO 2013

Eli Lilly, BIPI support ADA's call for independent review of incretin-based therapies

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

Study surveys physicians regarding prescribing of brand drugs over generics

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

Amedra Pharmaceuticals re-launches single-dose epinephrine auto-injector, Adrenaclick

Pfizer receives $2.15 billion settlement from Teva and Sun for patent-infringement damages

Teva to present abstracts on AZILECT at MDS meeting

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

Lineage Therapeutics announces US launch of generic epinephrine auto-injector

NICE Appraisal Committee reconfirms clinical effectiveness of ILUVIEN

Research: Older adults who volunteer for work decrease their risk of hypertension

IPC to distribute AP's Promescent in US for treatment of premature ejaculation

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence